Name: Latest research reports of Indegene Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Indegene Ltd.
Rating: 3
Author: Motilal Oswal

Indegene Ltd.

NSE: INDGN | BSE: 544172 | ISIN: INE065X01017 | Industry: Healthcare Services
| Mid-range Performer

472.6000 8.05 (1.73%)

NSE Apr 02, 2026 15:31 PM

25.33% Fall from 52W High

Volume: 186.6K

Indegene Ltd.

31 Jan 2026

472.60

1.73%

Acquisition drives growth with steady organic performance

Neutral: Indegene Ltd.

Motilal Oswal

Indegene’s 3QFY26 USD revenue rose 15.1% QoQ, aided by the BioPharm acquisition, while organic USD revenue growth stood at 4% QoQ (below our estimate).

Indegene Ltd. has an average target of 550.00 from 1 broker.